Rafael Holdings, Inc. (RFL) stock
RFLNYSEPharmaceutical PreparationsFiscal year ends July 31
$1.07−0.04 (-3.60%)
Close on Nov 13, 2026Market cap $55.84MP/E –Yield –
Rafael ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rafael's ebitda for the twelve months ending Jul 31, 2026 was -$33.21M. For fiscal 2026 it was -$33.21M. The highest annual figure on record is $2.84M in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$33.21M | – |
| FY2025 | Jul 31, 2025 | -$28.87M | – |
| FY2024 | Jul 31, 2024 | -$102.40M | – |
| FY2023 | Jul 31, 2023 | -$14.97M | – |
| FY2022 | Jul 31, 2022 | -$60.41M | – |
| FY2021 | Jul 31, 2021 | -$28.13M | – |
| FY2020 | Jul 31, 2020 | -$6.60M | – |
| FY2019 | Jul 31, 2019 | -$4.92M | – |
| FY2018 | Jul 31, 2018 | -$2.14M | -213.4% |
| FY2017 | Jul 31, 2017 | $1.89M | -33.3% |
| FY2016 | Jul 31, 2016 | $2.84M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -$9.68M | – |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -$6.82M | – |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -$6.60M | – |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -$10.09M | – |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | -$12.71M | – |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$5.85M | – |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -$6.55M | – |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -$3.76M | – |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$3.78M | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$93.06M | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$3.11M | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$2.46M | – |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$2.59M | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$3.01M | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$4.24M | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$5.12M | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$4.82M | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$4.67M | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$1.58M | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$49.52M | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$12.42M | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$3.28M | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$10.38M | – |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -$2.05M | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | -$2.60M | – |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | -$1.49M | – |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | -$1.43M | – |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | -$1.08M | – |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -$2.27M | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -$982.00K | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -$975.00K | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -$691.00K | – |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -$819.00K | -259.6% |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -$309.00K | -225.1% |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -$387.00K | -169.0% |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -$630.00K | – |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | $513.00K | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | $247.00K | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | $561.00K | – |
See a number that looks wrong?